Joy Yan, M.D., Ph.D.

Joy Yan, M.D., Ph.D., joined Ambrx’s Scientific Advisory Board (SAB) in January 2022. Joy is currently the Chief Medical Officer of KeyMed Biosciences, joining the company in January of 2022. Prior to transitioning to the SAB and her role at KeyMed, Joy served as Ambrx’s Chief Medical Officer from 2020 to January 2022. She is an oncology physician-scientist and executive with extensive experience in early and late clinical development. She has led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS’ first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. Joy also has broad clinical development experience through her time at Janssen and Bayer, where she led Phase I, II, and III studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, ADCs, Bispecifics, TKIs) across multiple tumor types. She has been successful in gaining FDA Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval, Priority Review, and Orphan Drug Designation for multiple programs with different tumor indications.

Dr. Yan completed her Ph.D. in Biochemistry & Molecular Biology at Johns Hopkins University and her M.D. from China Medical University. Joy completed her residency and clinical fellowship at University of Washington.